VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP).

ORAL VACCINES

Oral Vaccines. Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines.

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. VAXART COVID-19 VACCINE PILL OPINIONS AND ATTITUDES SURVEY 9. Americans overwhelmingly support innovations making coronavirus vaccines more accessible and easier to distribute. 75% . Want government funding for a wider range of drug companies VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP).

ORAL VACCINES

Oral Vaccines. Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines.

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. VAXART COVID-19 VACCINE PILL OPINIONS AND ATTITUDES SURVEY 9. Americans overwhelmingly support innovations making coronavirus vaccines more accessible and easier to distribute. 75% . Want government funding for a wider range of drug companies VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

ORAL VACCINES

Oral Vaccines. Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART’S ORAL COVID-19 VACCINE CANDIDATE INDUCES POTENT The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

VAXART TO PRESENT AT THE SVB LEERINK CYBERX SERIES Please contact your SVB Leerink representative to schedule virtual one-on-one meetings with Vaxart during the respective conference.. About CybeRx Series: Vaccine Forum The 2nd Annual CybeRx Series: Vaccine Forum will feature updates about COVID vaccine development, manufacturing and adoption. The event will also feature companies and academic experts that will discuss the future

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES ADDITIONAL PRECLINICAL COVID-19 ORAL Data from Vaxart’s Phase I COVID-19 trial expected to be released next week. SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its

SARS-CoV

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 Study reached primary and secondary endpoints of safety and immunogenicity, respectively; VXA-CoV2-1 induced potent CD8 + T-cell responses; VXA-CoV2-1 potentially protective against new and emerging

COVID-19 strains

VAXART COVID-19 VACCINE PILL OPINIONS AND ATTITUDES SURVEY 9. Americans overwhelmingly support innovations making coronavirus vaccines more accessible and easier to distribute. 75% . Want government funding for a wider range of drug companies SEC FILING | VAXART, INC. SEC Filing | Vaxart, Inc. SEC FORM 3. SEC Form 3. FORM 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES. Filed pursuant to Section 16 (a) of the Securities Exchange Act of 1934. or Section 30 (h) of the Investment Company Act of 1940. SEC FILING | VAXART, INC. President and Chief Executive Officer. 290 Utah Ave. Suite 200. South San Francisco, California 94080. (650) 550-3500. (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: John T. McKenna.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP).

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. VAXART COVID-19 VACCINE PILL OPINIONS AND ATTITUDES SURVEY 9. Americans overwhelmingly support innovations making coronavirus vaccines more accessible and easier to distribute. 75% . Want government funding for a wider range of drug companies

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP).

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. VAXART COVID-19 VACCINE PILL OPINIONS AND ATTITUDES SURVEY 9. Americans overwhelmingly support innovations making coronavirus vaccines more accessible and easier to distribute. 75% . Want government funding for a wider range of drug companies

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

ORAL VACCINES

Oral Vaccines. Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines. VAXART’S ORAL COVID-19 VACCINE CANDIDATE INDUCES POTENT The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART TO PRESENT AT THE SVB LEERINK CYBERX SERIES Please contact your SVB Leerink representative to schedule virtual one-on-one meetings with Vaxart during the respective conference.. About CybeRx Series: Vaccine Forum The 2nd Annual CybeRx Series: Vaccine Forum will feature updates about COVID vaccine development, manufacturing and adoption. The event will also feature companies and academic experts that will discuss the future VAXART ANNOUNCES ADDITIONAL PRECLINICAL COVID-19 ORAL Data from Vaxart’s Phase I COVID-19 trial expected to be released next week. SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its

SARS-CoV

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

VAXART COVID-19 VACCINE PILL OPINIONS AND ATTITUDES SURVEY 9. Americans overwhelmingly support innovations making coronavirus vaccines more accessible and easier to distribute. 75% . Want government funding for a wider range of drug companies SEC FILING | VAXART, INC. SEC Filing | Vaxart, Inc. SEC FORM 3. SEC Form 3. FORM 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES. Filed pursuant to Section 16 (a) of the Securities Exchange Act of 1934. or Section 30 (h) of the Investment Company Act of 1940. SEC FILING | VAXART, INC. President and Chief Executive Officer. 290 Utah Ave. Suite 200. South San Francisco, California 94080. (650) 550-3500. (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: John T. McKenna.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. CONTACT US – VAXART INC. Vaxart, Inc. Headquarters. 170 Harbor Way, Suite 300, South San Francisco, CA 94080 +1 650 550 3500 MAIN +1 650 871 8580 FAX VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART ANNOUNCES ADDITIONAL PRECLINICAL COVID-19 ORAL New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models. An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine. Data from Vaxart’s Phase I COVID-19 trial expected to be released next week

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILING | VAXART, INC. Item 2.02 Results of Operations and Financial Condition. Vaxart, Inc. (the “ Company ”) estimates that its cash and cash equivalents as of December 31, 2020, was approximately $126.9 million, compared to $13.5 million and $11.5 million as of December 31, 2019 and 2018, respectively. The increase in 2020 is primarily due to $97 million BIOTA AND NABI ANNOUNCE PROPOSED MERGER Biota and Nabi Announce Proposed Merger. MELBOURNE, AUSTRALIA -- (Marketwire) -- 04/23/12 -- Biota Holdings Limited (ASX: BTA) and Nabi Biopharmaceuticals (NASDAQ: NABI) today announced the signing of a Merger Implementation Agreement to form a combined company Biota Pharmaceuticals, listed on NASDAQ and headquartered in the USA.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. CONTACT US – VAXART INC. Vaxart, Inc. Headquarters. 170 Harbor Way, Suite 300, South San Francisco, CA 94080 +1 650 550 3500 MAIN +1 650 871 8580 FAX VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART ANNOUNCES ADDITIONAL PRECLINICAL COVID-19 ORAL New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models. An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine. Data from Vaxart’s Phase I COVID-19 trial expected to be released next week

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILING | VAXART, INC. Item 2.02 Results of Operations and Financial Condition. Vaxart, Inc. (the “ Company ”) estimates that its cash and cash equivalents as of December 31, 2020, was approximately $126.9 million, compared to $13.5 million and $11.5 million as of December 31, 2019 and 2018, respectively. The increase in 2020 is primarily due to $97 million BIOTA AND NABI ANNOUNCE PROPOSED MERGER Biota and Nabi Announce Proposed Merger. MELBOURNE, AUSTRALIA -- (Marketwire) -- 04/23/12 -- Biota Holdings Limited (ASX: BTA) and Nabi Biopharmaceuticals (NASDAQ: NABI) today announced the signing of a Merger Implementation Agreement to form a combined company Biota Pharmaceuticals, listed on NASDAQ and headquartered in the USA.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. CONTACT US – VAXART INC. Vaxart, Inc. Headquarters. 170 Harbor Way, Suite 300, South San Francisco, CA 94080 +1 650 550 3500 MAIN +1 650 871 8580 FAX VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART ANNOUNCES ADDITIONAL PRECLINICAL COVID-19 ORAL New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models. An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine. Data from Vaxart’s Phase I COVID-19 trial expected to be released next week

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILING | VAXART, INC. Item 2.02 Results of Operations and Financial Condition. Vaxart, Inc. (the “ Company ”) estimates that its cash and cash equivalents as of December 31, 2020, was approximately $126.9 million, compared to $13.5 million and $11.5 million as of December 31, 2019 and 2018, respectively. The increase in 2020 is primarily due to $97 million BIOTA AND NABI ANNOUNCE PROPOSED MERGER Biota and Nabi Announce Proposed Merger. MELBOURNE, AUSTRALIA -- (Marketwire) -- 04/23/12 -- Biota Holdings Limited (ASX: BTA) and Nabi Biopharmaceuticals (NASDAQ: NABI) today announced the signing of a Merger Implementation Agreement to form a combined company Biota Pharmaceuticals, listed on NASDAQ and headquartered in the USA.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

RICHARD MARKHAM

Richard Markham. Mr. Markham has served as a member of our board of directors since December 2009. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. CONTACT US – VAXART INC. Vaxart, Inc. Headquarters. 170 Harbor Way, Suite 300, South San Francisco, CA 94080 +1 650 550 3500 MAIN +1 650 871 8580 FAX VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART ANNOUNCES ADDITIONAL PRECLINICAL COVID-19 ORAL New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models. An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine. Data from Vaxart’s Phase I COVID-19 trial expected to be released next week

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILING | VAXART, INC. Item 2.02 Results of Operations and Financial Condition. Vaxart, Inc. (the “ Company ”) estimates that its cash and cash equivalents as of December 31, 2020, was approximately $126.9 million, compared to $13.5 million and $11.5 million as of December 31, 2019 and 2018, respectively. The increase in 2020 is primarily due to $97 million BIOTA AND NABI ANNOUNCE PROPOSED MERGER Biota and Nabi Announce Proposed Merger. MELBOURNE, AUSTRALIA -- (Marketwire) -- 04/23/12 -- Biota Holdings Limited (ASX: BTA) and Nabi Biopharmaceuticals (NASDAQ: NABI) today announced the signing of a Merger Implementation Agreement to form a combined company Biota Pharmaceuticals, listed on NASDAQ and headquartered in the USA.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

ORAL VACCINES

Oral Vaccines. Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines.

VACCINE ADVANTAGES

Advantages & Impact. Oral Delivery: A tablet is preferable to most people.No injection devices are necessary. Administration: The convenience of a tablet will make it easier to reach those who could benefit from immunization and simplify the vaccine administration process for healthcare providers. Temperature Stability: The Vaxart vaccine tablet has demonstrated room-temperature stability

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. NOROVIRUS – VAXART INC. Norovirus is the leading cause of acute viral gastroenteritis in all age groups in the U.S. Each year, on average, norovirus causes 19 to 21 million cases of acute gastroenteritis and leads to 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly among young children and older adults. Typical symptoms include dehydration,

vomiting

VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine. SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has INFLUENZA – VAXART INC. Influenza is a major cause of morbidity and mortality in the U.S. and worldwide. However, currently marketed vaccines have suboptimal efficacy and only 47% of eligible U.S. citizens were vaccinated in 2016-2017. Vaxart believes its tablet vaccine has the potential to improve the protective efficacy of currently available influenza

vaccines and

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with

VAXART INC.

Vaccines. Explore the history and impact of the rapidly growing $30 billion global vaccines market. LEARN MORE. Oral Recombinant Vaccines. Oral Recombinant Vaccines. Our platform supports the rapid development, manufacture and distribution of vaccines. LEARN MORE. NEWS – VAXART INC. Latest News. The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. PIPELINE – VAXART INC. Preclinical vaccine (dysplasia/cancer) See our Current Pipeline. We are currently focusing on the development of our coronavirus vaccine. We are actively looking for a partner for our influenza vaccine program. All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under good clinical practices (GCP). CAREERS – VAXART INC. Passionate. Collaborative. Vaxart stands at the forefront of the next generation of vaccines, poised to benefit global health with the goal of keeping healthy people healthy and improving the ease with which vaccines are developed, distributed, accessed and administered. Vaxart has demonstrated that its proprietary tablet vaccine delivery

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that 0001437749-20-005683 10-K. Filing Date. Mar 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings.

STOCK INFORMATION

The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

SEC FILINGS

SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a vote ("Proxy") Initial filing by director officer or owner of more than ten percent. VAXART ENTERS INTO RESEARCH COLLABORATION WITH JANSSEN TO Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with TECHNOLOGY – VAXART INC. Modular Vaccine Creation. The Vaxart tablet vaccine is composed of three basic elements: The vector: the Ad5 delivery vehicle that carries the DNA “payload” to the gut. The antigen: the pathogen protein designed to trigger the targeted immune response. The adjuvant: a “booster” molecule that stimulates and adds to the

immune response.

ORAL VACCINES

Oral Vaccines. Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines.

VACCINE ADVANTAGES

Advantages & Impact. Oral Delivery: A tablet is preferable to most people.No injection devices are necessary. Administration: The convenience of a tablet will make it easier to reach those who could benefit from immunization and simplify the vaccine administration process for healthcare providers. Temperature Stability: The Vaxart vaccine tablet has demonstrated room-temperature stability

INVESTOR OVERVIEW

In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Currently Vaxart is focused on development of a COVID-19 vaccine to address the current pandemic. NASDAQ CM: VXRT $6.62 -0.07 (-1.05%) Data Provided by Refinitiv. Minimum 15 minutes delayed. NOROVIRUS – VAXART INC. Norovirus is the leading cause of acute viral gastroenteritis in all age groups in the U.S. Each year, on average, norovirus causes 19 to 21 million cases of acute gastroenteritis and leads to 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly among young children and older adults. Typical symptoms include dehydration,

vomiting

VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year. Through Large Scale Lyophilization, Tableting and Coating . SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine. SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has INFLUENZA – VAXART INC. Influenza is a major cause of morbidity and mortality in the U.S. and worldwide. However, currently marketed vaccines have suboptimal efficacy and only 47% of eligible U.S. citizens were vaccinated in 2016-2017. Vaxart believes its tablet vaccine has the potential to improve the protective efficacy of currently available influenza

vaccines and

PRESS RELEASES

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean

Tucker , CSO of the

VAXART ANNOUNCES POSITIVE PRELIMINARY DATA FROM PHASE 1 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial

analysts.

* Investors

* News

* Careers

* Contact

* Global Need

* Vaccines

* History & Impact

* Our Solution

* Oral Vaccines

* Technology

* Vaccine Advantages * Platform Advantages

* Pipeline

* Research & Development

* Norovirus

* Influenza

* RSV

* HPV

* About Us

* Our Mission

* Our Team

* Careers

* Contact

* Compliance

* Investors

* News

* Careers

* Contact

UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Learn More

Learn More

VACCINES

VACCINES

Explore the history and impact of the rapidly growing $30 billion global vaccines market.

LEARN MORE

ORAL RECOMBINANT VACCINES ORAL RECOMBINANT VACCINES Our platform supports the rapid development, manufacture and distribution of vaccines.

LEARN MORE

PIPELINE

PIPELINE

Explore our development programs.

LEARN MORE

NEWS & PRESS

05/27/21

Vaxart to Present at the Jefferies Virtual Healthcare Conference

Read more

05/07/21

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Do..

Read more

05/04/21

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boo..

Read more

View More

� 2021 Vaxart, Inc., All rights reserved. Terms of Use

Privacy Policy